You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

Fig. 1

PET CT Imaging of Patient Undergoing Combination Ipilimumab/Nivolumab Immunotherapy. a left arrow, mesenteric lesion. right arrow, left upper extremity cutaneous lesion (1) prior to initiating combination ipilimumab/nivolumab therapy, (2) following the second dose of combination ipilimumab/nivolumab therapy. b (1) prior to initiating combination ipilimumab/nivolumab therapy, (2) following the second dose of combination ipilimumab/nivolumab therapy, (3) 1 year following the third dose of combination ipilimumab/nivolumab therapy and treatment discontinuation due to toxicity

Back to article page